Abstract
Thrombin a key modulator of the complex process involved in coronary obstruction during acute ST-segment elevation myocardial is infarction. A correct and complete thrombin inhibition has to be achieved early in this setting and is complementary with fast and potent antiplatelet treatment. Bivalirudin, a direct thrombin inhibitor, has clearly shown to be an effective tool for acute coronary syndromes managed invasively, contemporarily causing fewer hemorragies. However, its efficacy has been questioned, mostly in cases of inadequate platelet inhibition and during primary PCI if compared with therapy with heparin and glycoprotein IIb/IIIa inhibitors due to an increase in acute stent thrombosis. Other modalities of infusion have been shown to improve the antithrombotic properties of bivalirudin, maintaining its safety profile. In this article, we discuss on the most recent studies on this drug in the catheterization laboratory during acute myocardial infarction.
Keywords: STEMI, primary PCI, bivalirudin, prolonged infusion, glycoprotein IIb/IIIa inhibitors, thrombin, heparin, acute stent thrombosis, coronary atherosclerotic plaque, clopidogrel
Current Vascular Pharmacology
Title:In the Bivalirudin Era, Are We Still Looking for a Potent Antiplatelet Agent?
Volume: 10 Issue: 4
Author(s): Bernardo Cortese, Antonino Pitì, Adnan Kastrati and Dirk Sibbing
Affiliation:
Keywords: STEMI, primary PCI, bivalirudin, prolonged infusion, glycoprotein IIb/IIIa inhibitors, thrombin, heparin, acute stent thrombosis, coronary atherosclerotic plaque, clopidogrel
Abstract: Thrombin a key modulator of the complex process involved in coronary obstruction during acute ST-segment elevation myocardial is infarction. A correct and complete thrombin inhibition has to be achieved early in this setting and is complementary with fast and potent antiplatelet treatment. Bivalirudin, a direct thrombin inhibitor, has clearly shown to be an effective tool for acute coronary syndromes managed invasively, contemporarily causing fewer hemorragies. However, its efficacy has been questioned, mostly in cases of inadequate platelet inhibition and during primary PCI if compared with therapy with heparin and glycoprotein IIb/IIIa inhibitors due to an increase in acute stent thrombosis. Other modalities of infusion have been shown to improve the antithrombotic properties of bivalirudin, maintaining its safety profile. In this article, we discuss on the most recent studies on this drug in the catheterization laboratory during acute myocardial infarction.
Export Options
About this article
Cite this article as:
Cortese Bernardo, Pitì Antonino, Kastrati Adnan and Sibbing Dirk, In the Bivalirudin Era, Are We Still Looking for a Potent Antiplatelet Agent?, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812700
DOI https://dx.doi.org/10.2174/157016112800812700 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Strategies for Inhibition of Thrombin Activity
Current Pharmaceutical Design Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D<sub>2</sub> (Paricalcitol)
Current Vascular Pharmacology Design of a Genetically Modified Soybean Protein Preventing Hypertension Based on an Anti-Hypertensive Peptide Derived from Ovalbumin
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery Role of Inflammation in Diabetic Nephropathy
Current Diabetes Reviews Lipid Metabolism and Relevant Disorders to Female Reproductive Health
Current Medicinal Chemistry Evaluation of Different Methods for Assaying Protein Carbonylation
Current Analytical Chemistry Inhibitors of Protein-Protein Interactions as Potential Drugs
Current Computer-Aided Drug Design Microglial Activation with Reduction in Autophagy Limits White Matter Lesions and Improves Cognitive Defects During Cerebral Hypoperfusion
Current Neurovascular Research Prevalence of Anxiety During Pregnancy in Women with Previous Spontaneous Abortions
Current Women`s Health Reviews Therapeutic Potential of Coagonists of Glucagon and GLP-1
Cardiovascular & Hematological Agents in Medicinal Chemistry Uncoupling Proteins: Role in Insulin Resistance and Insulin Insufficiency
Current Diabetes Reviews Gender Differences in Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design Glycogen Synthase Kinase-3: A Potential Target for Drug Discovery in the Treatment of Neurodegenerative Disorders
Current Enzyme Inhibition Using Serum Biomarkers for Identifying Unstable Carotid Plaque: Update of Current Evidence
Current Pharmaceutical Design STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients – an Observational Study in Germany
Current Reviews in Clinical and Experimental Pharmacology Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges
Current Drug Targets Transcranial Direct Current Stimulation for Treatment of Alzheimer’s Disease: A Systematic Review of Randomized Clinical Trial
Current Psychiatry Reviews Quality Assessment of Clinical Practice Guidelines for the Prescription of Antidepressant Drugs During Pregnancy
Current Clinical Pharmacology